Rabusertib

Base Information

Chemical Name:Rabusertib
CAS No.:911222-45-2
Molecular Formula:C₁₈H₂₂BrN₅O₃
Molecular Weight:436.308
Hs Code.:29349990
UNII:3S9L1NU6U7
DSSTox Substance ID:DTXSID50238417
Nikkaji Number:J3.353.319E
Wikidata:Q27088510
NCI Thesaurus Code:C81937
Pharos Ligand ID:36R1C66PS325
Metabolomics Workbench ID:152780
ChEMBL ID:CHEMBL3039517
Mol file:911222-45-2.mol

Synonyms:LY2603618

Suppliers and Price of Rabusertib

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

TRC
LY2603618
10mg
$ 425.00

TRC
LY2603618
5mg
$ 275.00

Tocris
LY2603618 ≥98%(HPLC)
10
$ 216.00

Tocris
LY2603618 ≥98%(HPLC)
50
$ 906.00

DC Chemicals
LY2603618(IC-83) >98%
1 g
$ 1850.00

Crysdot
LY2603618 98+%
100mg
$ 795.00

Crysdot
LY2603618 98+%
50mg
$ 511.00

ChemScene
Rabusertib 99.69%
5mg
$ 108.00

ChemScene
Rabusertib 99.69%
10mg
$ 168.00

ChemScene
Rabusertib 99.69%
100mg
$ 840.00

Total 25 raw suppliers

Chemical Property of Rabusertib

Chemical Property:

Boiling Point:503.1±50.0 °C(Predicted)
PKA:12.06±0.70(Predicted)
PSA：100.89000
Density:1.461
LogP:3.28250
Storage Temp.:-20°C
Solubility.:Soluble in DMSO (up to 10 mg/ml)
XLogP3:1.4
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:5
Exact Mass:435.09060
Heavy Atom Count:27
Complexity:486

Purity/Quality:

99%, ^*data from raw suppliers

LY2603618 ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Canonical SMILES:CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OCC3CNCCO3
Isomeric SMILES:CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OC[C@@H]3CNCCO3
Recent ClinicalTrials:A Study of Advanced or Metastatic Non-small Cell Lung Cancer
Recent EU Clinical Trials:A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer
Description LY2603618 is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated. LY2603618 (911222-45-2) is a potent (IC50?= 7nM) and selective (>1000x over Chk2) Checkpoint kinase 1 (Chk1) inhibitor.1?Chk1 is an important regulator of the DNA damage response – combination treatment of LY2603618 with other chemotherapeutic agents significantly increased tumor growth inhibition when compared to chemotherapeutic alone.2,3,4?LY2603618 caused a dramatic suppression of cell growth in MCF-7 and MDA-MB-231 human breast cancer cells?via?Chk1 inhibition induced upregulation of replication stress caused by oncogenes.5
Uses LY2603618 is a selective Chk1 inhibitor that can treat idiopathic pulmonary fibrosis.

Technology Process of Rabusertib

There total 1 articles about Rabusertib which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: